Sarepta Therapeutics, Inc.

Passed

Class Action Period:
September 06, 2017 - August 19, 2019

Lead Plaintiff Deadline:
October 29, 2019

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Allegations

(i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until October 29, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.